Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal

BACKGROUND: Primary FSGS manifests with nephrotic syndrome and may recur following KT. Failure to respond to conventional therapy after recurrence results in poor outcomes. Evaluation of podocyte B7-1 expression and treatment with abatacept (a B7-1 antagonist) has shown promise but remains controver...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, George W., Chandar, Jayanthi, Sageshima, Junichiro, Ortigosa-Goggins, Mariella, Amarapurkar, Pooja, Mitrofanova, Alla, Defreitas, Marissa J., Katsoufis, Chryso P., Seeherunvong, Wacharee, Centeno, Alexandra, Pagan, Javier, Mendez-Castaner, Lumen A., Mattiazzi, Adela D., Kupin, Warren L., Guerra, Giselle, Chen, Linda J., Morsi, Mahmoud, Figueiro, Jose M. G., Vianna, Rodrigo, Abitbol, Carolyn L., Roth, David, Fornoni, Alessia, Ruiz, Phillip, Ciancio, Gaetano, Garin, Eduardo H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747833/
https://www.ncbi.nlm.nih.gov/pubmed/35507150
http://dx.doi.org/10.1007/s00467-022-05549-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747833/
https://www.ncbi.nlm.nih.gov/pubmed/35507150
http://dx.doi.org/10.1007/s00467-022-05549-7

Ejemplares similares